Browse the evidence

The presence of metabolic abnormalities doubles event rates associated with obesity, with risk increasing with the number of metabolic abnormalities present.

Practitioners should consider the presence of metabolic abnormalities when assessing the risks of obesity in patients.

Adverse events were more frequent in the semaglutide group, including gastrointestinal intolerance and infections.

Clinicians should be aware of the higher incidence of adverse events with semaglutide.

Metabolic parameters such as glycaemic, blood pressure, and lipid levels return to baseline within approximately 12 months after discontinuation.

Healthcare providers should monitor metabolic parameters closely after discontinuation of GLP-1RA therapy.

The benefits of GLP-1R agonists may be enhanced by stimulating other receptors.

Combining GLP-1R agonists with other receptor agonists may enhance therapeutic outcomes.

At 2.5 years, White individuals experienced significantly greater body weight loss than Black individuals: −7.1% versus −4.9%.

Practitioners should be aware of racial differences in weight loss outcomes when prescribing GLP-1RA therapy.

White individuals had significantly larger reductions in estimated glomerular filtration rate, systolic blood pressure, and HbA1c compared to Black individuals.

Healthcare providers should consider these differences in clinical outcomes when treating patients with GLP-1RA.

Future clinical trials are needed to clarify the mechanisms of benefit and define the role of weight-reduction therapies in obesity-related HFpEF.

Clinicians should be aware that ongoing research may further inform treatment strategies for obesity-related HFpEF.

Emerging single-anastomosis variants demonstrate promising efficacy and improved gastrointestinal profiles.

Clinicians should consider these emerging techniques for patients seeking bariatric surgery.

Among patients who discontinued treatment, 72% did not demonstrate weight regain.

Clinicians may find that many patients can maintain weight after stopping GLP-1RA therapy.

KN069 was well tolerated, with predominantly mild-to-moderate gastrointestinal adverse events.

KN069 may be a safe option for weight management in this population.

Unerwünschte Wirkungen von Semaglutid sind gut dokumentiert, insbesondere gastrointestinale Beschwerden.

Ärzte sollten über die häufigsten Nebenwirkungen von Semaglutid informiert sein, um Patienten entsprechend zu beraten.

Obesity and obstructive sleep apnea (OSA) contribute to cardiovascular disease through interconnected mechanisms.

Practitioners should consider the combined effects of obesity and OSA when addressing cardiovascular health.

Maximal and sustained benefit of GLP-1 receptor agonists may be compromised by poor compliance and cessation of use.

Practitioners should address compliance issues when prescribing GLP-1 receptor agonists.

28.1% of eligible patients were current users of GLP-1 receptor agonists.

A notable proportion of eligible OSA patients are utilizing GLP-1 RAs, indicating potential treatment pathways.

Having Medicaid was associated with a lower likelihood of using GLP-1 receptor agonists among eligible patients.

Practitioners should be aware that socioeconomic factors, such as Medicaid coverage, may influence GLP-1 RA utilization.

GLP-1 RA use was associated with significantly lower occupational therapy utilization (RR = 0.686, p < 0.011).

GLP-1 RAs may reduce the need for occupational therapy in rotator cuff repair patients.

GLP-1 RA users had higher rates of cardiovascular complications (RR = 1.426, p = 0.038).

Practitioners should monitor cardiovascular health in patients using GLP-1 RAs.

The Deep Reinforcement Learning (DRL) agent decreased gastrointestinal (GI) adverse events incidence by 35% and severity by 42% in simulations.

Implementing a DRL agent for dosing may significantly reduce GI side effects in patients.

Muscle volume decreased in the injured muscle compared to the contralateral healthy muscle during the intervention by −9.4% (−13.5% to −5.3%), p < 0.0001, and this decrease persisted at 12 months.

Rehabilitation programs should consider the persistent loss of muscle volume after strain injuries.

There was a persistent increase in aponeurosis volume associated with the injured muscle at 3 months and 12 months, but it was unaffected by protein supplementation.

Increased aponeurosis volume may indicate structural changes in muscle healing, regardless of protein intake.

There was no significant effect of whey or soy protein supplementation on lean body mass (LBM) or squat performance.

Practitioners should note that whey and soy protein may not significantly impact LBM or squat performance.

Neither collagen nor whey protein ingestion further increased muscle connective protein synthesis rates during the early stages of post-exercise recovery.

Collagen protein may not be effective for enhancing muscle connective tissue recovery post-exercise.

There was no significant effect of either whey or soy protein supplementation on lean body mass (LBM).

Practitioners should note that protein supplementation may not significantly increase lean body mass.

There is significant heterogeneity in the theoretical models and psychometric properties of existing tools assessing DEAB in athletes.

Practitioners should be cautious when interpreting results from various DEAB assessment tools due to their differing foundations and properties.